Related references
Note: Only part of the references are listed.A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Julie Westerlin Kjeldsen et al.
NATURE MEDICINE (2021)
Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy
Lucas A. Horn et al.
CANCERS (2021)
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Alexander M. M. Eggermont et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for the treatment of uveal melanoma: A case series
Yanina Jeanne Leona Jansen et al.
RARE TUMORS (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Ernesto Rossi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
Vivek Verma et al.
NATURE IMMUNOLOGY (2019)
Mechanisms of Resistance to PD-1 and PD-L1 Blockade
Theodore S. Nowicki et al.
CANCER JOURNAL (2018)
Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer
Douglas G. McNeel et al.
Oncotarget (2018)
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial
Lea Lowenfeld et al.
CLINICAL CANCER RESEARCH (2017)
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer
Grainne M. O'Kane et al.
ONCOLOGIST (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
Vaccines targeting helper T cells for cancer immunotherapy
Marit Meissen et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J. Messenheimer et al.
CLINICAL CANCER RESEARCH (2017)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival
Caroline M. Reed et al.
CLINICAL CANCER RESEARCH (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine
Yinin Hu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection
Alison Crawford et al.
IMMUNITY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes
Patrick M. Dillon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)
Craig L. Slingluff et al.
CLINICAL CANCER RESEARCH (2013)
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine
Craig L. Slingluff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines
Craig L. Jr M. D. Slingluff et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens
Craig L. Slingluff et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunologic and clinical outcomes of a Randomized phase II trial of two multipeptide Vaccines for melanoma in the adjuvant setting
Craig L. Slingluff et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
